Fact CheckerSign in

NCT07420075Enrolling by invitation

Alzheimer's Registry

PPD™ CorEvitas™ International Alzheimer's (ALZ) Drug Safety and Effectiveness Registry

Source: ClinicalTrials.gov · Last updated 19 Feb 2026

Brief summary (registry, in English)

The design is an open-ended, prospective, observational, (non-interventional) registry for subjects with mild cognitive impairment (MCI), early symptomatic Alzheimer's disease, Alzheimer's disease, or dementia with clinical suspicion of Alzheimer's disease under the care of a neurologist, psychiatrist, geriatrician or other qualified provider. Longitudinal data are collected from subjects, their care partner(s), and their treating healthcare provider during routine clinical encounters using a structured and standardized data collection method. Approximately 2,000 subjects, with no defined upper limit, across around 75 clinical sites worldwide will be recruited.

Status (registry)
Enrolling by invitation
Study type
Observational
Enrollment
2000 (estimated)
First submitted
4 Feb 2026
Start date
24 Nov 2025
Primary completion date
31 Dec 2099
Lead sponsor
CorEvitas
NCT number
NCT07420075

What you commit to

  • Study type: Observational
  • Planned participants: 2000
  • From 24 Nov 2025 to the primary completion date, 31 Dec 2099
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Has been previously treated with an ATT prior to enrollment into the registry

Other

  • An individual who meets any of the following criteria will be excluded from participation in the registry:
  • Is participating or planning to participate in a double-blind randomized clinical trial for a MCI or AD.

Who the study is looking for

  • To be eligible to participate in this registry, an individual must meet all the following criteria (determined by the investigator):
  • Has been diagnosed with mild cognitive impairment (MCI), early symptomatic Alzheimer's disease, Alzheimer's disease, or dementia with clinical suspicion of Alzheimer's disease.
  • Subject is at least 18 years of age or older and has attained the legal age for consent to procedures involved in the research, under the applicable law of the jurisdiction in which the research is being conducted at the time of enrollment.
  • Has care partner(s) willing to participate as a source of information who maintains regular contact with the subject (defined as at least ten hours per week), will accompany the subject to the clinic visits, has attained the legal age for consent under the applicable law of jurisdiction in which the research is being conducted at the time of consent, and is willing and able to provide informed consent as the care partner.
  • Subject has the ability to understand the purpose, risks, and voluntariness of Registry participation and is willing and able to provide informed consent
  • For US subjects only, must be willing and able to provide Personally Identifiable Information (full legal name, sex at birth, date of birth, home address zip/postal code, and social security number at a minimum).
  • Has been prescribed (and intends to initiate) a commercially available therapy for the treatment of Alzheimer's disease (or symptoms of Alzheimer's disease) (Eligible Medication) at the time of enrollment.
    • Note: Participation in the registry will not interfere with the standard of care provided by the subject's treating clinician. Investigators retain independent clinical judgment in managing patient care.

Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
CorEvitas, LLC
Coordinator of this site? Confirm its status
WalthamUnited StatesUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.